Chantal Donovan

Dr. Chantal Donovan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
RKRichard Y. Kim
Richard Y. Kim
KSKrishna P. Sunkara
Krishna P. Sunkara
KBKen R. Bracke
Ken R. Bracke
AJAndrew G. Jarnicki
Andrew G. Jarnicki
CDChantal Donovan
Chantal Donovan
PHPhilip M. Hansbro
Philip M. Hansbro
Inhibition of cigarette smoke–induced microRNA-21 suppresses chronic obstructive pulmonary disease through effects on a SATB1/S100A9/NF-κB axis.

8 February 2024 in Gut
Verified
Journal Article
Closed access
PDF file
Kurtis Francis BuddenKurtis Francis Budden
Kurtis Francis Budden
SSShakti Shukla
Shakti Shukla
KBKate L Bowerman
Kate L Bowerman
AVAnnalicia Vaughan
Annalicia Vaughan
SGShaan L Gellatly
Shaan L Gellatly
PHPhilip M. Hansbro
Philip M. Hansbro
Objective: Chronic obstructive pulmonary disease (COPD) is a major cause of global illness and death, most commonly caused by cigarette smoke. The mechanisms of pathogenesis remain poorly understood, limiting the development of effective therapies. The gastrointestinal microbiome has been implicated in chronic lung diseases via the gut-lung axis, but its role is unclear. Design: Using an in vivo mouse model of cigarette smoke (CS)-induced COPD and faecal microbial transfer (FMT), we characterised the faecal microbiota using metagenomics, proteomics and metabolomics. Findings were correlated with airway and systemic inflammation, lung and gut histopathology and lung function. Complex carbohydrates were assessed in mice using a high resistant starch diet, and in 16 patients with COPD using a randomised, double-blind, placebo-controlled pilot study of inulin supplementation. Results: FMT alleviated hallmark features of COPD (inflammation, alveolar destruction, impaired lung function), gastrointestinal pathology and systemic immune changes. Protective effects were additive to smoking cessation, and transfer of CS-associated microbiota after antibiotic-induced microbiome depletion was sufficient to increase lung inflammation while suppressing colonic immunity in the absence of CS exposure. Disease features correlated with the relative abundance of Muribaculaceae, Desulfovibrionaceae and Lachnospiraceae family members. Proteomics and metabolomics identified downregulation of glucose and starch metabolism in CS-associated microbiota, and supplementation of mice or human patients with complex carbohydrates improved disease outcomes. Conclusion: The gut microbiome contributes to COPD pathogenesis and can be targeted therapeutically.

20 December 2019 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
CDChantal Donovan
Chantal Donovan
PHPhilip M. Hansbro
Philip M. Hansbro

16 March 2023 in Frontiers in Physiology
Verified
Journal Article
Open access
OCOlivia R. Carroll
Olivia R. Carroll
APAmber L. Pillar
Amber L. Pillar
ABAlexandra C. Brown
Alexandra C. Brown
MFMin Feng
Min Feng
HCHui Chen
Hui Chen
CDChantal Donovan
Chantal Donovan
Recent advances in mouse models of experimental asthma coupled with vast improvements in systems that assess respiratory physiology have considerably increased the accuracy and human relevance of the outputs from these studies. In fact, these models have become important pre-clinical testing platforms with proven value and their capacity to be rapidly adapted to interrogate emerging clinical concepts, including the recent discovery of different asthma phenotypes and endotypes, has accelerated the discovery of disease-causing mechanisms and increased our understanding of asthma pathogenesis and the associated effects on lung physiology. In this review, we discuss key distinctions in respiratory physiology between asthma and severe asthma, including the magnitude of airway hyperresponsiveness and recently discovered disease drivers that underpin this phenomenon such as structural changes, airway remodeling, airway smooth muscle hypertrophy, altered airway smooth muscle calcium signaling, and inflammation. We also explore state-of-the-art mouse lung function measurement techniques that accurately recapitulate the human scenario as well as recent advances in precision cut lung slices and cell culture systems. Furthermore, we consider how these techniques have been applied to recently developed mouse models of asthma, severe asthma, and asthma-chronic obstructive pulmonary disease overlap, to examine the effects of clinically relevant exposures (including ovalbumin, house dust mite antigen in the absence or presence of cigarette smoke, cockroach allergen, pollen, and respiratory microbes) and to increase our understanding of lung physiology in these diseases and identify new therapeutic targets. Lastly, we focus on recent studies that examine the effects of diet on asthma outcomes, including high fat diet and asthma, low iron diet during pregnancy and predisposition to asthma development in offspring, and environmental exposures on asthma outcomes. We conclude our review with a discussion of new clinical concepts in asthma and severe asthma that warrant investigation and how we could utilize mouse models and advanced lung physiology measurement systems to identify factors and mechanisms with potential for therapeutic targeting.

17 January 2025 in Journal of Experimental Medicine
Verified
Journal Article
Open access
WAWael Awad
Wael Awad
JMJemma R. Mayall
Jemma R. Mayall
WXWeijun Xu
Weijun Xu
Matt JohansenMatt Johansen
Matt Johansen
TPTimothy Patton
Timothy Patton
JRJamie Rossjohn
Jamie Rossjohn
Tobacco smoking is prevalent across the world and causes numerous diseases. Cigarette smoke (CS) compromises immunity, yet little is known of the components of CS that impact T cell function. MR1 is a ubiquitous molecule that presents bacterial metabolites to MAIT cells, which are highly abundant in the lungs. Using in silico, cellular, and biochemical approaches, we identified components of CS that bind MR1 and impact MR1 cell surface expression. Compounds, including nicotinaldehyde, phenylpropanoid, and benzaldehyde-related scaffolds, bound within the A′ pocket of MR1. CS inhibited MAIT cell activation, ex vivo, via TCR-dependent and TCR-independent mechanisms. Chronic CS exposure altered MAIT cell phenotype and function and attenuated MAIT cell responses to influenza A virus infection in vivo. MR1-deficient mice were partially protected from the development of chronic obstructive pulmonary disease (COPD) features that were associated with CS exposure. Thus, CS can impair MAIT cell function by diverse mechanisms, and potentially contribute to infection susceptibility and disease exacerbations.

19 August 2020 in Science Translational Medicine
Verified
Journal Article
Open access
RPRudi Prihandoko
Rudi Prihandoko
DKDavinder Kaur
Davinder Kaur
CWCoen H. Wiegman
Coen H. Wiegman
EAElisa Alvarez-Curto
Elisa Alvarez-Curto
CDChantal Donovan
Chantal Donovan
ATAndrew B. Tobin
Andrew B. Tobin
FFA4 receptor agonism corrects dysfunctional lung responses and inflammation in models and is a potential target for inflammatory lung disease.